Features and Outcomes of 280 Patients With Idiosyncratic Drug-Induced Liver Injury: The REFHEPS Prospective Study.
(2026) Clinical Gastroenterology and Hepatology — Vol. 24, n° 7, p. 1854-1866 (2026)
Files
1-s2.0-S1542356525009334 (1).pdf
Open Access - Adobe PDF
- 1.21 MB
Details
- Authors
Meunier, Lucy 
- Abstract
- *Authors share co-first authorship. § Authors share co-senior authorship. Abbreviations used in this paper: ALF, acute liver failure; ALP, alkaline phosphatase; ALT, alanine aminotransferase; CDK4/6, cyclin-dependent kinase 4/6; CIOMS, Council for International Organizations of Medical Sciences; DILI, drug-induced liver injury; DILIN, Drug-Induced Liver Injury Network; HDS, herbal and dietary supplements; HER, human epidermal growth factor receptor; ICIs, immune checkpoint inhibitors; IQR, inter-quartile range; KRAS, Kirsten rat sarcoma viral oncogene homolog; LT, liver transplantation; OTC, over-the-counter (medications); REFHEPS, Réseau d'Étude Francophone de l'Hépatotoxicité des Produits de Santé; RUCAM, Roussel-Uclaf Causality Assessment Method; SD, standard deviation; TBL, total bilirubin; UDCA, ursodeoxycholic acid; ULN, upper limit of normal. Most current article
- Affiliations
Citations
Meunier, L., Delire, B., De Martin, E., Lebossé, F., Anty, R., Dumortier, J., Houssel-Debry, P., Delwaide, J., Duclos-Vallee, J.-C., Lutu, A., Lemoinne, S., Roux, O., Péron, J.-M., Saviano, A., Abergel, A., Prost, A., Hountondji, L., Thabut, D., Dharancy, S., et al. (2026). Features and Outcomes of 280 Patients With Idiosyncratic Drug-Induced Liver Injury: The REFHEPS Prospective Study. Clinical Gastroenterology and Hepatology, 24(7), 1854-1866. https://doi.org/10.1016/j.cgh.2025.10.024 (Original work published 2026)